# Ravi Salgia

## List of Publications by Year in Descending Order

**Source:** https://exaly.com/author-pdf/2223928/ravi-salgia-publications-by-year.pdf
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|---|---|---|---|
| 384 papers | 26,527 citations | 80 h-index | 155 g-index |
| 415 ext. papers | 30,021 ext. citations | 6.2 avg, IF | 6.88 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 384 | Co-opting disorder into order: Intrinsically disordered proteins and the early evolution of complex multicellularity.. *International Journal of Biological Macromolecules*, **2022**, 201, 29-36 | 7.9 | 1 |
| 383 | Intrinsically Disordered Proteins: Critical Components of the Wetware.. *Chemical Reviews*, **2022**, | 68.1 | 4 |
| 382 | Intrinsically disordered proteins: Ensembles at the limits of Anfinsen's dogma. *Biophysics Reviews*, **2022**, 3, 011306 | 2.6 | 1 |
| 381 | AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.. *BMC Cancer*, **2022**, 22, 447 | 4.8 | 0 |
| 380 | Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma.. *Frontiers in Pharmacology*, **2021**, 12, 806570 | 5.6 | 0 |
| 379 | Protein conformational dynamics and phenotypic switching.. *Biophysical Reviews*, **2021**, 13, 1127-1138 | 3.7 | 0 |
| 378 | Response. *Chest*, **2021**, 160, e375-e376 | 5.3 | |
| 377 | Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer. *Frontiers in Oncology*, **2021**, 11, 621088 | 5.3 | 3 |
| 376 | RNA-based therapies: A cog in the wheel of lung cancer defense. *Molecular Cancer*, **2021**, 20, 54 | 42.1 | 17 |
| 375 | Disparate outcomes in nonsmall cell lung cancer by immigration status. *Cancer Medicine*, **2021**, 10, 2660-2667 | 4.8 | 1 |
| 374 | Germline mutations and age at onset of lung adenocarcinoma. *Cancer*, **2021**, 127, 2801-2806 | 6.4 | 2 |
| 373 | Group Behavior and Emergence of Cancer Drug Resistance. *Trends in Cancer*, **2021**, 7, 323-334 | 12.5 | 6 |
| 372 | Activating p53 function by targeting RLIP. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2021**, 1875, 188512 | 11.2 | 0 |
| 371 | Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. *Nature Communications*, **2021**, 12, 3039 | 17.4 | 5 |
| 370 | ST6GalNAc-I promotes lung cancer metastasis by altering MUC5AC sialylation. *Molecular Oncology*, **2021**, 15, 1866-1881 | 7.9 | 2 |
| 369 | The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin -Like 1--Catenin Protein Complex. *Journal of Pharmacology and Experimental Therapeutics*, **2021**, 378, 77-86 | 4.7 | 0 |
| 368 | Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic. *Kidney Cancer*, **2021**, 5, 73-78 | 0.6 | |

| | | | |
|---|---|---|---|
| 367 | Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. *Journal of Thoracic Oncology*, **2021**, 16, 1030-1041 | 8.9 | 26 |
| 366 | The Association between Polluted Neighborhoods and -Mutated Non-Small Cell Lung Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 1498-1505 | 4 | 0 |
| 365 | Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). *British Journal of Cancer*, **2021**, 125, 582-592 | 8.7 | 1 |
| 364 | Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma. *Clinical Lung Cancer*, **2021**, | 4.9 | 1 |
| 363 | Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions. *Cancers*, **2021**, 13, | 6.6 | 1 |
| 362 | Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. *Molecular Cancer Therapeutics*, **2021**, 20, 1820-1835 | 6.1 | 1 |
| 361 | Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer. *Cureus*, **2021**, 13, e16266 | 1.2 | 3 |
| 360 | Targeting RLIP with CRISPR/Cas9 controls tumor growth. *Carcinogenesis*, **2021**, 42, 48-57 | 4.6 | 4 |
| 359 | Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. *JCO Oncology Practice*, **2021**, 17, e257-e265 | 2.3 | 2 |
| 358 | Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis?. *JCO Oncology Practice*, **2021**, 17, 52-53 | 2.3 | |
| 357 | Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. *Clinical Colorectal Cancer*, **2021**, 20, e129-e138 | 3.8 | 0 |
| 356 | JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted -Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies. *JTO Clinical and Research Reports*, **2021**, 2, 100103 | 1.4 | 3 |
| 355 | The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States. *Clinical Lung Cancer*, **2021**, 22, e84-e97 | 4.9 | 4 |
| 354 | The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). *Cell Reports Medicine*, **2021**, 2, 100186 | 18 | 27 |
| 353 | Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: A Review and the City of Hope Experience. *Journal of Clinical Medicine*, **2021**, 10, | 5.1 | 1 |
| 352 | Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP. *Molecular Carcinogenesis*, **2021**, 60, 213-223 | 5 | 0 |
| 351 | RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. *Carcinogenesis*, **2021**, 42, 742-752 | 4.6 | 2 |
| 350 | Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. *Oncologist*, **2021**, 26, 1052-1061 | 5.7 | 7 |

| | | | |
|---|---|---|---|
| 349 | Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey. *JCO Oncology Practice*, **2021**, 17, e1120-e1130 | 2.3 | 2 |
| 348 | Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. *Chest*, **2021**, 160, 1095-1107 | 5.3 | 7 |
| 347 | Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. *Clinical Lung Cancer*, **2021**, 22, e703-e707 | 4.9 | 0 |
| 346 | Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy. *Clinical Lung Cancer*, **2021**, 22, e678-e683 | 4.9 | 0 |
| 345 | Targeting the mercapturic acid pathway for the treatment of melanoma. *Cancer Letters*, **2021**, 518, 10-22 | 9.9 | 3 |
| 344 | Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy.. *Biomolecules*, **2021**, 12, | 5.9 | 4 |
| 343 | Infectious complications of immune checkpoint inhibitors in solid organ malignancies. *Cancer Medicine*, **2021**, | 4.8 | 6 |
| 342 | Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. *Journal of Thoracic Disease*, **2020**, 12, 5096-5103 | 2.6 | |
| 341 | Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. *Journal of Thoracic Disease*, **2020**, 12, 5086-5095 | 2.6 | 9 |
| 340 | Therapeutic targeting of miRNA-216b in cancer. *Cancer Letters*, **2020**, 484, 16-28 | 9.9 | 6 |
| 339 | Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach. *Frontiers in Oncology*, **2020**, 10, 593 | 5.3 | 10 |
| 338 | Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 9 |
| 337 | Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. *Lung Cancer*, **2020**, 146, 174-181 | 5.9 | 5 |
| 336 | Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. *Cancer Cell*, **2020**, 38, 79-96.e11 | 24.3 | 145 |
| 335 | Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. *Magnetic Resonance Imaging*, **2020**, 69, 49-56 | 3.3 | 8 |
| 334 | Implementing Lung Cancer Screening and Prevention in Academic Centers, Affiliated Network Offices and Collaborating Care Sites. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 3 |
| 333 | Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid Modeling. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 1 |
| 332 | MET receptor in oncology: From biomarker to therapeutic target. *Advances in Cancer Research*, **2020**, 147, 259-301 | 5.9 | 9 |

| | | | |
|---|---|---|---|
| 331 | Association of Polymorphisms with Breast Cancer Risk: A Meta-Analysis of Case-Control Studies  *Cancers*, **2020**, 12, | 6.6 | 1 |
| 330 | Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. *Future Oncology*, **2020**, 16, 4289-4301 | 3.6 | 6 |
| 329 | Precision medicine and actionable alterations in lung cancer: A single institution experience. *PLoS ONE*, **2020**, 15, e0228188 | 3.7 | 4 |
| 328 | The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. *Cancer Treatment Reviews*, **2020**, 87, 102022 | 14.4 | 30 |
| 327 | Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. *Molecular Cancer Therapeutics*, **2020**, 19, 1210-1217 | 6.1 | 13 |
| 326 | AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. *Clinical Cancer Research*, **2020**, 26, 4349-4359 | 12.9 | 12 |
| 325 | Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).. *Journal of Clinical Oncology*, **2020**, 38, TPS9080-TPS9080 | 3.3 | 2 |
| 324 | The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy. *Oncotarget*, **2020**, 11, 1953-1960 | 3.3 | 4 |
| 323 | Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). *Cancers*, **2020**, 13, | 6.6 | 8 |
| 322 | Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. *International Journal of Oncology*, **2020**, 57, 80-86 | 4.4 | 1 |
| 321 | Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring exon 14 mutation: a research report. *Journal of Physical Education and Sports Management*, **2020**, 6, | 2.8 | 6 |
| 320 | SOX9: The master regulator of cell fate in breast cancer. *Biochemical Pharmacology*, **2020**, 174, 113789 | 6 | 21 |
| 319 | Presence and structure-activity relationship of intrinsically disordered regions across mucins. *FASEB Journal*, **2020**, 34, 1939-1957 | 0.9 | 4 |
| 318 | RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2020**, 1873, 188337 | 11.2 | 3 |
| 317 | Phenotypic switching and prostate diseases: a model proposing a causal link between benign prostatic hyperplasia and prostate cancer **2020**, 569-589 | | |
| 316 | Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas. *IScience*, **2020**, 23, 101692 | 6.1 | 3 |
| 315 | Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. *Seminars in Cancer Biology*, **2020**, | 12.7 | 11 |
| 314 | A Non-genetic Mechanism Involving the Integrin /Paxillin Axis Contributes to Chemoresistance in Lung Cancer. *IScience*, **2020**, 23, 101496 | 6.1 | 7 |

| | | | |
|---|---|---|---|
| 313 | Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 6 |
| 312 | Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics. *Journal of Biological Chemistry*, **2020**, 295, 13393-13406 | 5.4 | 7 |
| 311 | -Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. *Biomedicines*, **2020**, 8, | 4.8 | 6 |
| 310 | Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. *Cancers*, **2020**, 12, | 6.6 | 11 |
| 309 | The Mitochondrion as an Emerging Therapeutic Target in Cancer. *Trends in Molecular Medicine*, **2020**, 26, 119-134 | 11.5 | 57 |
| 308 | USP22 Interacts with PALB2 and Promotes Chemotherapy Resistance via Homologous Recombination of DNA Double-Strand Breaks. *Molecular Cancer Research*, **2020**, 18, 424-435 | 6.6 | 5 |
| 307 | Co-stimulatory and co-inhibitory immune markers in solid tumors with alterations. *Future Science OA*, **2020**, 7, FSO662 | 2.7 | 0 |
| 306 | Precision medicine and actionable alterations in lung cancer: A single institution experience **2020**, 15, e0228188 | | |
| 305 | Precision medicine and actionable alterations in lung cancer: A single institution experience **2020**, 15, e0228188 | | |
| 304 | Precision medicine and actionable alterations in lung cancer: A single institution experience **2020**, 15, e0228188 | | |
| 303 | Precision medicine and actionable alterations in lung cancer: A single institution experience **2020**, 15, e0228188 | | |
| 302 | EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. *Oncogenesis*, **2019**, 8, 49 | 6.6 | 10 |
| 301 | RLIP inhibition suppresses breast-to-lung metastasis. *Cancer Letters*, **2019**, 447, 24-32 | 9.9 | 10 |
| 300 | Targeted Therapies in Non-small-Cell Lung Cancer. *Cancer Treatment and Research*, **2019**, 178, 3-43 | 3.5 | 11 |
| 299 | Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. *Lung Cancer*, **2019**, 133, 136-143 | 5.9 | 11 |
| 298 | Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice. *Molecular Carcinogenesis*, **2019**, 58, 1438-1449 | 5 | 9 |
| 297 | Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level. *Biomolecules*, **2019**, 9, | 5.9 | 11 |
| 296 | Combined Checkpoint Inhibition and Chemotherapy: New Era of 1-Line Treatment for Non-Small-Cell Lung Cancer. *Molecular Therapy - Oncolytics*, **2019**, 13, 1-6 | 6.4 | 22 |

| | | | |
|---|---|---|---|
| 295 | Early mortality of stage IV non-small cell lung cancer in the United States. *Acta Oncologica*, **2019**, 58, 1095-1101 | 3.2 | 2 |
| 294 | RLIP: An existential requirement for breast carcinogenesis. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2019**, 1871, 281-288 | 11.2 | 9 |
| 293 | Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. *Journal of Thoracic Oncology*, **2019**, 14, 1704-1717 | 8.9 | 6 |
| 292 | Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology. *Journal of Clinical Medicine*, **2019**, 8, | 5.1 | 6 |
| 291 | Notch signaling in breast cancer: From pathway analysis to therapy. *Cancer Letters*, **2019**, 461, 123-131 | 9.9 | 29 |
| 290 | Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. *Journal of Clinical Pharmacology*, **2019**, 59, 1632-1640 | 2.9 | 4 |
| 289 | The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. *Clinical and Translational Medicine*, **2019**, 8, 9 | 5.7 | 58 |
| 288 | Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. *Journal of Thoracic Oncology*, **2019**, 14, 1718-1731 | 8.9 | 9 |
| 287 | Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells. *Journal of Clinical Medicine*, **2019**, 8, | 5.1 | 2 |
| 286 | Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. *Journal of Clinical Medicine*, **2019**, 8, | 5.1 | 12 |
| 285 | Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).. *Journal of Clinical Oncology*, **2019**, 37, TPS8577-TPS8577 | 2.2 | 10 |
| 284 | MET as a Therapeutic Target: Have Clinical Outcomes Been MET in Lung Cancer?. *Current Cancer Research*, **2019**, 101-123 | 0.2 | |
| 283 | Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.. *Journal of Clinical Oncology*, **2019**, 37, 9093-9093 | 2.2 | 2 |
| 282 | Lung cancer in African-Americans and analysis of estrogen plus progestin use.. *Journal of Clinical Oncology*, **2019**, 37, e18258-e18258 | 2.2 | |
| 281 | Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2019**, 42, 337-344 | 2.7 | 5 |
| 280 | Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer. *Cell Communication and Signaling*, **2019**, 17, 167 | 7.5 | 25 |
| 279 | Opportunities for improving cancer treatment using systems biology. *Current Opinion in Systems Biology*, **2019**, 17, 41-50 | 3.2 | 2 |
| 278 | The DNA walk and its demonstration of deterministic chaos-relevance to genomic alterations in lung cancer. *Bioinformatics*, **2019**, 35, 2738-2748 | 7.2 | 4 |

| | | | |
|---|---|---|---|
| 277 | 2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells. *Journal of Proteomics*, **2019**, 192, 233-245 | 3.9 | 9 |
| 276 | The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. *Future Oncology*, **2018**, 14, 1897-1908 | 3.6 | 5 |
| 275 | EphB4: A promising target for upper aerodigestive malignancies. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2018**, 1869, 128-137 | 11.2 | 9 |
| 274 | The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. *Trends in Cancer*, **2018**, 4, 110-118 | 12.5 | 123 |
| 273 | Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. *Cancer Biology and Therapy*, **2018**, 19, 316-327 | 4.6 | 53 |
| 272 | Untying the gordion knot of targeting MET in cancer. *Cancer Treatment Reviews*, **2018**, 66, 95-103 | 14.4 | 14 |
| 271 | B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. *Cell*, **2018**, 173, 470-484.e18 | 56.2 | 62 |
| 270 | Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2018**, 41, 963-966 | 2.7 | 4 |
| 269 | Effective osimertinib treatment in a patient with discordant T790M mutation detection between liquid biopsy and tissue biopsy. *BMC Cancer*, **2018**, 18, 314 | 4.8 | 5 |
| 268 | Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations **2018**, 6, 8 | | 606 |
| 267 | 2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76. *Molecular Carcinogenesis*, **2018**, 57, 1751-1762 | 5 | 18 |
| 266 | Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. *European Urology*, **2018**, 74, 124-128 | 10.2 | 33 |
| 265 | 2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer. *Oncotarget*, **2018**, 9, 18053-18068 | 3.3 | 15 |
| 264 | Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients. *Oncotarget*, **2018**, 9, 19793-19806 | 3.3 | 22 |
| 263 | Heuristic value-based framework for lung cancer decision-making. *Oncotarget*, **2018**, 9, 29877-29891 | 3.3 | 3 |
| 262 | Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting **2018**, 4, 49-54 | | 13 |
| 261 | Differential Response of MET inhibition by Glesatinib (MGCD265) and Sitravatinib (MGCD516) in Non-small Cell Lung Cancer and Malignant Mesothelioma. *FASEB Journal*, **2018**, 32, 835.9 | 0.9 | |
| 260 | Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer. *Journal of Oncology Practice*, **2018**, 14, 569-571 | 3.1 | 4 |

| | | | |
|---|---|---|---|
| 259 | Managing Patients With Relapsed Small-Cell Lung Cancer. *Journal of Oncology Practice*, **2018**, 14, 359-366 | 3.1 | 23 |
| 258 | Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. *Clinical and Translational Medicine*, **2018**, 7, 32 | 5.7 | 20 |
| 257 | Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. *Journal of Clinical Medicine*, **2018**, 7, | 5.1 | 8 |
| 256 | Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. *Journal of Thoracic Oncology*, **2018**, 13, 1655-1667 | 8.9 | 50 |
| 255 | Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma. *Cancer Biology and Therapy*, **2018**, 19, 1023-1032 | 4.6 | 9 |
| 254 | Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. *Oncotarget*, **2018**, 9, 26226-26242 | 3.3 | 10 |
| 253 | Value-based genomics. *Oncotarget*, **2018**, 9, 15792-15815 | 3.3 | 30 |
| 252 | Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone. *Cancer Letters*, **2018**, 438, 144-153 | 9.9 | 9 |
| 251 | Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. *Seminars in Oncology*, **2018**, 45, 210-219 | 5.5 | 23 |
| 250 | A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. *Cancer Chemotherapy and Pharmacology*, **2018**, 82, 309-317 | 3.5 | 9 |
| 249 | A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. *Lung Cancer*, **2017**, 105, 7-13 | 5.9 | 33 |
| 248 | Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. *International Journal of Cancer*, **2017**, 141, 766-777 | 7.5 | 19 |
| 247 | Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer. *Oncology Letters*, **2017**, 13, 4027-4034 | 2.6 | 3 |
| 246 | The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. *Cancer Treatment Reviews*, **2017**, 55, 181-189 | 14.4 | 9 |
| 245 | TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. *Cancer Science*, **2017**, 108, 488-496 | 6.9 | 25 |
| 244 | MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. *Molecular Cancer Therapeutics*, **2017**, 16, 555-565 | 6.1 | 92 |
| 243 | Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. *Investigational New Drugs*, **2017**, 35, 334-344 | 4.3 | 23 |
| 242 | The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. *Science Signaling*, **2017**, 10, | 8.8 | 32 |

| | | | |
|---|---|---|---|
| 241 | Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. *Scientific Reports*, **2017**, 7, 9192 | 4.9 | 11 |
| 240 | Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention. *European Journal of Oncology Nursing*, **2017**, 29, 125-134 | 2.8 | 25 |
| 239 | Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. *Oncotarget*, **2017**, 8, 67639-67650 | 3.3 | 20 |
| 238 | Value-Based Medicine and Integration of Tumor Biology. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 833-840 | 7.1 | 3 |
| 237 | Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. *Oncotarget*, **2017**, 8, 42198-42213 | 3.3 | 30 |
| 236 | Value-Based Medicine and Integration of Tumor Biology. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 833-840 | 7.1 | 2 |
| 235 | Genomic mutation-driven metastatic breast cancer therapy: a single center experience. *Oncotarget*, **2017**, 8, 26414-26423 | 3.3 | 8 |
| 234 | Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. *Oncotarget*, **2017**, 8, 43733-43751 | 3.3 | 15 |
| 233 | State-of-the-art considerations in small cell lung cancer brain metastases. *Oncotarget*, **2017**, 8, 71223-71233 | 3.3 | 33 |
| 232 | Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. *Oncotarget*, **2017**, 8, 18726-18734 | 3.3 | 5 |
| 231 | Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. *Cancer Letters*, **2016**, 380, 494-504 | 9.9 | 102 |
| 230 | Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. *Molecular Cancer Therapeutics*, **2016**, 15, 2175-86 | 6.1 | 30 |
| 229 | Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. *Scientific Reports*, **2016**, 6, 24578 | 4.9 | 27 |
| 228 | Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. *Lancet Oncology, The*, **2016**, 17, 1683-1696 | 21.7 | 224 |
| 227 | PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. *Scientific Reports*, **2016**, 6, 32992 | 4.9 | 18 |
| 226 | Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. *Oncologist*, **2016**, 21, 762-70 | 5.7 | 87 |
| 225 | Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. *Future Oncology*, **2016**, 12, 1045-58 | 3.6 | 7 |
| 224 | Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. *Journal of Thoracic Oncology*, **2016**, 11, 453-74 | 8.9 | 106 |

| | | | |
|---|---|---|---|
| 223 | C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype. *Cancer Biology and Therapy*, **2016**, 17, 91-103 | 4.6 | 3 |
| 222 | Tumor Heterogeneity and Therapeutic Resistance. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 36, e585-e593 | 7.1 | 12 |
| 221 | Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. *Oncotarget*, **2016**, 7, 13621-33 | 3.3 | 36 |
| 220 | Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. *Oncotarget*, **2016**, 7, 18876-86 | 3.3 | 20 |
| 219 | FAK and paxillin, two potential targets in pancreatic cancer. *Oncotarget*, **2016**, 7, 31586-601 | 3.3 | 67 |
| 218 | Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. *Cureus*, **2016**, 8, e513 | 1.2 | 14 |
| 217 | Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. *Oncotarget*, **2016**, 7, 66880-66891 | 3.3 | 48 |
| 216 | Tumor Heterogeneity and Therapeutic Resistance. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, e585-93 | 7.1 | 19 |
| 215 | Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. *BMC Cancer*, **2016**, 16, 568 | 4.8 | 1 |
| 214 | Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. *JAMA Oncology*, **2016**, 2, 805-12 | 13.4 | 92 |
| 213 | Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. *Expert Review of Molecular Diagnostics*, **2016**, 16, 737-49 | 3.8 | 20 |
| 212 | A new PET/CT volumetric prognostic index for non-small cell lung cancer. *Lung Cancer*, **2015**, 89, 43-9 | 5.9 | 15 |
| 211 | Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. *Clinical Cancer Research*, **2015**, 21, 4321-6 | 12.9 | 47 |
| 210 | Lung cancer-a fractal viewpoint. *Nature Reviews Clinical Oncology*, **2015**, 12, 664-75 | 19.4 | 91 |
| 209 | Engineering Synthetic Antibody Inhibitors Specific for LD2 or LD4 Motifs of Paxillin. *Journal of Molecular Biology*, **2015**, 427, 2532-2547 | 6.5 | 6 |
| 208 | A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. *Expert Opinion on Drug Safety*, **2015**, 14, 485-93 | 4.1 | 10 |
| 207 | AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. *Clinical Cancer Research*, **2015**, 21, 2601-12 | 12.9 | 71 |
| 206 | Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. *Journal of Thoracic Oncology*, **2015**, 10, S1-63 | 8.9 | 102 |

| | | | |
|---|---|---|---|
| 205 | A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. *Molecular Cancer Therapeutics*, **2015**, 14, 461-9 | 6.1 | 22 |
| 204 | Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. *Journal of Clinical Oncology*, **2015**, 33, 4284-92 | 2.2 | 323 |
| 203 | Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. *Future Oncology*, **2015**, 11, 489-500 | 3.6 | 17 |
| 202 | PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma. *Journal of Biological Chemistry*, **2015**, 290, 21901-14 | 5.4 | 17 |
| 201 | ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy. *Journal of Clinical Neuroscience*, **2015**, 22, 1978-9 | 2.2 | 4 |
| 200 | Whole-animal mounts of Caenorhabditis elegans for 3D imaging using atomic force microscopy. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2015**, 11, 1971-4 | 6 | 10 |
| 199 | Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. *Clinical Cancer Research*, **2015**, 21, 870-81 | 12.9 | 242 |
| 198 | Role played by paxillin and paxillin tyrosine phosphorylation in hepatocyte growth factor/sphingosine-1-phosphate-mediated reactive oxygen species generation, lamellipodia formation, and endothelial barrier function. *Pulmonary Circulation*, **2015**, 5, 619-30 | 2.7 | 16 |
| 197 | Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. *Scientific Reports*, **2015**, 5, 10641 | 4.9 | 16 |
| 196 | Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2015**, 38, 442-7 | 2.7 | 6 |
| 195 | HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression. *Frontiers in Oncology*, **2015**, 5, 164 | 5.3 | 19 |
| 194 | Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. *Cancer Discovery*, **2015**, 5, 850-9 | 24.4 | 460 |
| 193 | c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2015**, 308, L1025-38 | 5.8 | 21 |
| 192 | Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC).. *Journal of Clinical Oncology*, **2015**, 33, 7567-7567 | 2.2 | 1 |
| 191 | Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. *Cancer Letters*, **2014**, 343, 14-23 | 9.9 | 18 |
| 190 | Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. *Journal of Biological Chemistry*, **2014**, 289, 13476-91 | 5.4 | 56 |
| 189 | Crizotinib in ROS1-rearranged non-small-cell lung cancer. *New England Journal of Medicine*, **2014**, 371, 1963-71 | 59.2 | 1267 |
| 188 | Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression. *Journal of Biological Chemistry*, **2014**, 289, 24043-58 | 5.4 | 30 |

| | | | |
|---|---|---|---|
| 187 | Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. *Molecular Cancer Therapeutics*, **2014**, 13, 1356-68 | 6.1 | 40 |
| 186 | Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. *Journal of Clinical Oncology*, **2014**, 32, 2328-34 | 2.2 | 95 |
| 185 | AXL mediates resistance to cetuximab therapy. *Cancer Research*, **2014**, 74, 5152-64 | 10.1 | 140 |
| 184 | Mitochondrial dynamics: biology and therapy in lung cancer. *Expert Opinion on Investigational Drugs*, **2014**, 23, 675-92 | 5.9 | 27 |
| 183 | Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. *Cancer Research*, **2014**, 74, 884-95 | 10.1 | 46 |
| 182 | Activating the expression of human K-rasG12D stimulates oncogenic transformation in transgenic goat fetal fibroblast cells. *PLoS ONE*, **2014**, 9, e90059 | 3.7 | 3 |
| 181 | The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. *PLoS ONE*, **2014**, 9, e91577 | 3.7 | 132 |
| 180 | Molecular pathways and therapeutic targets in lung cancer. *Oncotarget*, **2014**, 5, 1392-433 | 3.3 | 135 |
| 179 | Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. *Case Reports in Clinical Pathology*, **2014**, 1, 151-154 | 0.1 | 10 |
| 178 | Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. *CNS Oncology*, **2014**, 3, 61-75 | 4 | 9 |
| 177 | Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. *Clinical Cancer Research*, **2014**, 20, 1666-75 | 12.9 | 52 |
| 176 | Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition. *Growth Factors*, **2014**, 32, 202-6 | 1.6 | 8 |
| 175 | A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. *Advances in Experimental Medicine and Biology*, **2014**, 799, 85-117 | 3.6 | 76 |
| 174 | Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. *Cancer Medicine*, **2014**, 3, 681-92 | 4.8 | 20 |
| 173 | Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. *BMC Cancer*, **2014**, 14, 185 | 4.8 | 10 |
| 172 | Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. *Clinical Cancer Research*, **2014**, 20, 6336-45 | 12.9 | 61 |
| 171 | Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening. *Journal of Medical Screening*, **2014**, 21, 207-15 | 1.4 | 18 |
| 170 | Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. *Molecular Cancer Therapeutics*, **2014**, 13, 576-84 | 6.1 | 15 |

| | | | |
|---|---|---|---|
| 169 | MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. *PLoS ONE*, **2014**, 9, e105919 | 3.7 | 42 |
| 168 | EphB4 as a therapeutic target in mesothelioma. *BMC Cancer*, **2013**, 13, 269 | 4.8 | 23 |
| 167 | MET as a possible target for non-small-cell lung cancer. *Journal of Clinical Oncology*, **2013**, 31, 1089-96 | 2.2 | 152 |
| 166 | A new hope for precision medicine. *Science Translational Medicine*, **2013**, 5, 208fs38 | 17.5 | |
| 165 | Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. *Journal of Clinical Oncology*, **2013**, 31, e254-8 | 2.2 | 25 |
| 164 | Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. *Cancer Research*, **2013**, 73, 184-94 | 10.1 | 36 |
| 163 | Critical role of S1PR1 and integrin # in HGF/c-Met-mediated increases in vascular integrity. *Journal of Biological Chemistry*, **2013**, 288, 2191-200 | 5.4 | 29 |
| 162 | A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. *Clinical Cancer Research*, **2013**, 19, 3068-77 | 12.9 | 192 |
| 161 | Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. *Cancer Biology and Therapy*, **2013**, 14, 679-91 | 4.6 | 30 |
| 160 | The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. *PLoS ONE*, **2013**, 8, e67668 | 3.7 | 43 |
| 159 | Etoposide and Temozolomide in Combination for the Treatment of Progressive Small-Cell Lung Cancer Central Nervous System Metastases: Two Cases. *Tumori*, **2013**, 99, e73-e76 | 1.7 | 1 |
| 158 | Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis. *International Journal of Medical Sciences*, **2013**, 10, 988-94 | 3.7 | 19 |
| 157 | Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. *Journal of Thoracic and Cardiovascular Surgery*, **2012**, 144, 25-33 | 1.5 | 89 |
| 156 | The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. *Journal of Thoracic and Cardiovascular Surgery*, **2012**, 144, 33-8 | 1.5 | 438 |
| 155 | Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. *Journal of Thoracic Oncology*, **2012**, 7, S372-4 | 8.9 | 6 |
| 154 | Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. *Lancet Oncology, The*, **2012**, 13, 1011-9 | 21.7 | 983 |
| 153 | Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. *Annals of Thoracic Surgery*, **2012**, 94, 1086-92 | 2.7 | 35 |
| 152 | Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. *Targeted Oncology*, **2012**, 7, 199-210 | 5 | 25 |

| | | | |
|---|---|---|---|
| 151 | A novel classification of lung cancer into molecular subtypes. *PLoS ONE*, **2012**, 7, e31906 | 3.7 | 82 |
| 150 | Differential expression of RON in small and non-small cell lung cancers. *Genes Chromosomes and Cancer*, **2012**, 51, 841-51 | 5 | 31 |
| 149 | Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. *FASEB Journal*, **2012**, 26, 2175-86 | 0.9 | 359 |
| 148 | Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. *Clinical Lung Cancer*, **2012**, 13, 123-8 | 4.9 | 9 |
| 147 | Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. *ImmunoTargets and Therapy*, **2012**, 2012, 7-12 | 9 | 18 |
| 146 | Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. *Journal of Thoracic Oncology*, **2012**, 7, 376-81 | 8.9 | 88 |
| 145 | Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. *Journal of Thoracic Oncology*, **2012**, 7, 856-65 | 8.9 | 33 |
| 144 | Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. *International Surgery*, **2012**, 97, 65-70 | 0.1 | 2 |
| 143 | Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases. *Journal of Neurology Research*, **2012**, 2, 1-9 | 2.5 | 5 |
| 142 | Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. *Journal of Clinical Bioinformatics*, **2011**, 1, 1-11 | | 8 |
| 141 | Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncology, The*, **2011**, 12, 1004-12 | 21.7 | 732 |
| 140 | Role of MetMAb (OA-5D5) in c-MET active lung malignancies. *Expert Opinion on Biological Therapy*, **2011**, 11, 1655-62 | 5.4 | 43 |
| 139 | Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. *Journal of Thoracic Oncology*, **2011**, 6, S1810-1 | 8.9 | 6 |
| 138 | MET and phosphorylated MET as potential biomarkers in lung cancer. *Journal of Environmental Pathology, Toxicology and Oncology*, **2011**, 30, 341-54 | 2.1 | 19 |
| 137 | The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. *Anesthesia and Analgesia*, **2011**, 112, 558-67 | 3.9 | 183 |
| 136 | Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. *Journal of Thoracic Oncology*, **2011**, 6, 1418-25 | 8.9 | 51 |
| 135 | Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). *Journal of Thoracic Oncology*, **2011**, 6, 1741-5 | 8.9 | 9 |
| 134 | Generation of comprehensive thoracic oncology database--tool for translational research. *Journal of Visualized Experiments*, **2011**, | 1.6 | 4 |

| | | | |
|---|---|---|---|
| 133 | Personalized treatment of lung cancer. *Seminars in Oncology*, **2011**, 38, 274-83 | 5.5 | 33 |
| 132 | Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. *Cancer*, **2011**, 117, 3889-99 | 6.4 | 40 |
| 131 | An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. *Cancer*, **2011**, 117, 5344-50 | 6.4 | 25 |
| 130 | RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. *Cancer Biology and Therapy*, **2011**, 12, 9-46 | 4.6 | 72 |
| 129 | Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. *Journal of Clinical Oncology*, **2011**, 29, 2660-6 | 2.2 | 433 |
| 128 | Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. *Clinical Cancer Research*, **2011**, 17, 3112-22 | 12.9 | 24 |
| 127 | Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. *Journal of Thoracic Oncology*, **2011**, 6, 942-6 | 8.9 | 354 |
| 126 | Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. *Clinical Cancer Research*, **2011**, 17, 5257-67 | 12.9 | 67 |
| 125 | Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. *Journal of Clinical Pathology*, **2011**, 64, 16-24 | 3.9 | 36 |
| 124 | Takotsubo cardiomyopathy in a patient with squamous cell esophageal carcinoma. *Journal of Clinical Oncology*, **2011**, 29, e598-600 | 2.2 | 7 |
| 123 | Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. *Cancer Research*, **2011**, 71, 2423-7 | 10.1 | 40 |
| 122 | Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. *Journal of Thoracic Oncology*, **2011**, 6, 786-9 | 8.9 | 14 |
| 121 | MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. *Journal of Clinical Oncology*, **2011**, 29, 4803-10 | 2.2 | 364 |
| 120 | Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. *Cancer Discovery*, **2011**, 1, 573-9 | 24.4 | 94 |
| 119 | The role of the c-Met pathway in lung cancer and the potential for targeted therapy. *Therapeutic Advances in Medical Oncology*, **2011**, 3, 171-84 | 5.4 | 93 |
| 118 | Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer. *Drugs of the Future*, **2011**, 36, 91-99 | 2.3 | 10 |
| 117 | CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. *PLoS ONE*, **2010**, 5, e8972 | 3.7 | 85 |
| 116 | EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. *Journal of Biological Chemistry*, **2010**, 285, 18575-85 | 5.4 | 84 |

| | | | |
|---|---|---|---|
| 115 | Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *New England Journal of Medicine*, **2010**, 363, 1693-703 | 59.2 | 3577 |
| 114 | Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. *Journal of Biological Chemistry*, **2010**, 285, 32596-605 | 5.4 | 35 |
| 113 | DIFFERENTIAL SERUM LEVEL OF SPECIFIC HAPTOGLOBIN ISOFORMS IN SMALL CELL LUNG CANCER. *Current Proteomics*, **2010**, 7, 49-65 | 0.7 | 18 |
| 112 | MET molecular mechanisms and therapies in lung cancer. *Cell Adhesion and Migration*, **2010**, 4, 146-52 | 3.2 | 49 |
| 111 | The role of chemokine receptor CXCR4 in lung cancer. *Cancer Biology and Therapy*, **2010**, 9, 409-16 | 4.6 | 49 |
| 110 | Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. *Journal of Thoracic Oncology*, **2010**, 5, 2044-6 | 8.9 | 69 |
| 109 | Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. *Archives of Pathology and Laboratory Medicine*, **2010**, 134, 1702-5 | 5 | 33 |
| 108 | The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. *Cancer Research*, **2009**, 69, 3021-31 | 10.1 | 220 |
| 107 | The role of EGFR inhibition in the treatment of non-small cell lung cancer. *Oncologist*, **2009**, 14, 1116-30 | 5.7 | 44 |
| 106 | PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. *Journal of Biological Chemistry*, **2009**, 284, 27524-32 | 5.4 | 36 |
| 105 | Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. *Cancer Research*, **2009**, 69, 7538-47 | 10.1 | 63 |
| 104 | Ethnic differences and functional analysis of MET mutations in lung cancer. *Clinical Cancer Research*, **2009**, 15, 5714-23 | 12.9 | 151 |
| 103 | Role of c-Met in cancer: emphasis on lung cancer. *Seminars in Oncology*, **2009**, 36, S52-8 | 5.5 | 43 |
| 102 | PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. *Laboratory Investigation*, **2009**, 89, 301-14 | 5.9 | 74 |
| 101 | FYN is overexpressed in human prostate cancer. *BJU International*, **2009**, 103, 171-7 | 5.6 | 68 |
| 100 | The MET axis as a therapeutic target. *Update on Cancer Therapeutics*, **2009**, 3, 109-118 | | 28 |
| 99 | MET as a target for treatment of chest tumors. *Lung Cancer*, **2009**, 63, 169-79 | 5.9 | 105 |
| 98 | MET pathway as a therapeutic target. *Journal of Thoracic Oncology*, **2009**, 4, 444-7 | 8.9 | 45 |

| | | | |
|---|---|---|---|
| 97 | MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. *Journal of Environmental Pathology, Toxicology and Oncology*, **2009**, 28, 89-98 | 2.1 | 34 |
| 96 | NADPH Oxidases Are Important Regulators of Growth and Migration in Myeloid Neoplasms.. *Blood*, **2009**, 114, 2190-2190 | 2.2 | |
| 95 | Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. *Gynecologic Oncology*, **2008**, 110, 49-55 | 4.9 | 141 |
| 94 | Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. *Journal of Carcinogenesis*, **2008**, 7, 9 | 1.9 | 160 |
| 93 | C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. *Cancer Biology and Therapy*, **2008**, 7, 856-63 | 4.6 | 28 |
| 92 | Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. *Journal of Clinical Oncology*, **2008**, 26, 870-6 | 2.2 | 142 |
| 91 | Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. *Clinical Cancer Research*, **2008**, 14, 3896-905 | 12.9 | 27 |
| 90 | Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. *Cancer Research*, **2008**, 68, 132-42 | 10.1 | 96 |
| 89 | Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. *Journal of Thoracic Oncology*, **2008**, 3, 1003-11 | 8.9 | 54 |
| 88 | Protein kinase C beta in malignant pleural mesothelioma. *Anti-Cancer Drugs*, **2008**, 19, 841-8 | 2.4 | 9 |
| 87 | EGFR-targeted therapeutics: focus on SCCHN and NSCLC. *Scientific World Journal, The*, **2008**, 8, 909-19 | 2.2 | 19 |
| 86 | Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. *Cancer Chemotherapy and Pharmacology*, **2008**, 61, 549-58 | 3.5 | 61 |
| 85 | Expression and mutational analysis of MET in human solid cancers. *Genes Chromosomes and Cancer*, **2008**, 47, 1025-37 | 5 | 246 |
| 84 | Novel Transforming Mutations of CBL in Human Acute Myeloid Leukemia. *Blood*, **2008**, 112, 2948-2948 | 2.2 | 2 |
| 83 | Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. *Archives of Pathology and Laboratory Medicine*, **2008**, 132, 1882-8 | 5 | 16 |
| 82 | Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. *Mass Spectrometry Reviews*, **2007**, 26, 451-66 | 11 | 47 |
| 81 | Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin. *Cellular Signalling*, **2007**, 19, 2329-38 | 4.9 | 29 |
| 80 | c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. *Current Oncology Reports*, **2007**, 9, 102-8 | 6.3 | 107 |

| | | | |
|---|---|---|---|
| 79 | c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. *Cancer Research*, **2007**, 67, 1670-9 | 10.1 | 217 |
| 78 | Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2007**, 292, L1488-94 | 5.8 | 46 |
| 77 | Tyrosine kinase mutations in human cancer. *Current Molecular Medicine*, **2007**, 7, 77-84 | 2.5 | 53 |
| 76 | Lung carcinoma in African Americans. *Nature Clinical Practice Oncology*, **2007**, 4, 118-29 | | 41 |
| 75 | A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. *Cancer Research*, **2007**, 67, 3529-34 | 10.1 | 114 |
| 74 | A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. *Clinical Cancer Research*, **2007**, 13, 515-22 | 12.9 | 80 |
| 73 | CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. *Journal of Biological Chemistry*, **2007**, 282, 30643-57 | 5.4 | 102 |
| 72 | Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2007**, 30, 258-63 | 2.7 | 8 |
| 71 | Review of clinic trials: agents targeting c-Met. *Reviews on Recent Clinical Trials*, **2007**, 2, 143-7 | 1.2 | 25 |
| 70 | c-Met is a potentially new therapeutic target for treatment of human melanoma. *Clinical Cancer Research*, **2007**, 13, 2246-53 | 12.9 | 141 |
| 69 | A review of topoisomerase inhibition in lung cancer. *Cancer Biology and Therapy*, **2006**, 5, 1600-7 | 4.6 | 26 |
| 68 | Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. *Clinical Cancer Research*, **2006**, 12, 7261-70 | 12.9 | 163 |
| 67 | Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. *Cancer Research*, **2006**, 66, 352-61 | 10.1 | 171 |
| 66 | Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. *Nature Clinical Practice Oncology*, **2006**, 3, 50-7; quiz 1 p following 57 | | 102 |
| 65 | Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. *Respirology*, **2006**, 11, 687-92 | 3.6 | 27 |
| 64 | c-Met inhibition. *Clinical Advances in Hematology and Oncology*, **2006**, 4, 823-4 | 0.6 | 4 |
| 63 | Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. *Blood*, **2005**, 105, 1717-23 | 2.2 | 187 |
| 62 | Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. *Cancer Research*, **2005**, 65, 1479-88 | 10.1 | 470 |

| | | | |
|---|---|---|---|
| 61 | c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. *Cancer Letters*, **2005**, 225, 1-26 | 9.9 | 440 |
| 60 | A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. *Clinical Cancer Research*, **2005**, 11, 2312-9 | 12.9 | 114 |
| 59 | Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2. *Cancer Research*, **2005**, 65, 5301-9 | 10.1 | 36 |
| 58 | Receptor tyrosine kinases and inhibitors in lung cancer. *Scientific World Journal, The*, **2004**, 4, 589-604 | 2.2 | 28 |
| 57 | Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. *Clinical Cancer Research*, **2004**, 10, 3020-8 | 12.9 | 48 |
| 56 | The role of ephrins and Eph receptors in cancer. *Cytokine and Growth Factor Reviews*, **2004**, 15, 419-33 | 17.9 | 272 |
| 55 | Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1. *Annals of Thoracic Surgery*, **2004**, 78, 450-7 | 2.7 | 16 |
| 54 | Novel targets for therapeutic agents in small cell lung cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2004**, 2, 165-72 | 7.3 | 6 |
| 53 | Therapeutic targeting of the receptor tyrosine kinase Met. *Cancer Treatment and Research*, **2004**, 119, 121-38 | 3.5 | 13 |
| 52 | Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. *Anticancer Research*, **2004**, 24, 1031-8 | 2.3 | 68 |
| 51 | 2-methoxyestradiol alters cell motility, migration, and adhesion. *Blood*, **2003**, 102, 289-96 | 2.2 | 41 |
| 50 | c-Met: structure, functions and potential for therapeutic inhibition. *Cancer and Metastasis Reviews*, **2003**, 22, 309-25 | 9.6 | 379 |
| 49 | Benefit of active treatment in non-small-cell lung cancer in elderly patients and patients with poor performance status. *Clinical Lung Cancer*, **2003**, 5, 86-9 | 4.9 | 4 |
| 48 | Molecular and cellular biology of small cell lung cancer. *Seminars in Oncology*, **2003**, 30, 57-71 | 5.5 | 54 |
| 47 | Small cell lung cancer: from molecular biology to novel therapeutics. *Journal of Experimental Therapeutics and Oncology*, **2003**, 3, 305-18 | 0.8 | 12 |
| 46 | Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. *Oncologist*, **2003**, 8, 69-75 | 5.7 | 40 |
| 45 | Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. *Journal of Clinical Oncology*, **2003**, 21, 624-30 | 2.2 | 242 |
| 44 | Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate. *Journal of Clinical Oncology*, **2003**, 21, 2437-8 | 2.2 | 10 |

| | | | |
|---|---|---|---|
| 43 | Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. *Anticancer Research*, **2003**, 23, 49-62 | 2.3 | 24 |
| 42 | Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors. *Anticancer Research*, **2003**, 23, 3379-96 | 2.3 | 15 |
| 41 | A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. *Cancer Research*, **2003**, 63, 5462-9 | 10.1 | 166 |
| 40 | c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. *Cancer Research*, **2003**, 63, 6272-81 | 10.1 | 311 |
| 39 | p53 and Bcl-2 in small cell-lung cancer. *Clinical Lung Cancer*, **2003**, 4, 303 | 4.9 | |
| 38 | Phase II study of imatinib in patients with small cell lung cancer. *Clinical Cancer Research*, **2003**, 9, 5880-7 | 12.9 | 124 |
| 37 | Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. *Oncogene*, **2002**, 21, 1423-33 | 9.2 | 23 |
| 36 | Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. *Journal of Biological Chemistry*, **2002**, 277, 7875-81 | 5.4 | 143 |
| 35 | ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 6919-24 | 11.5 | 40 |
| 34 | CD2 molecules redistribute to the uropod during T cell scanning: implications for cellular activation and immune surveillance. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 7582-7 | 11.5 | 42 |
| 33 | A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. *Journal of Biological Chemistry*, **2002**, 277, 20887-94 | 5.4 | 44 |
| 32 | Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. *Cytokine and Growth Factor Reviews*, **2002**, 13, 41-59 | 17.9 | 341 |
| 31 | Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. *Clinical Cancer Research*, **2002**, 8, 620-7 | 12.9 | 167 |
| 30 | Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. *Cancer Research*, **2002**, 62, 5242-7 | 10.1 | 92 |
| 29 | Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. *Cancer Research*, **2002**, 62, 6304-11 | 10.1 | 180 |
| 28 | Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. *Cancer Chemotherapy and Pharmacology*, **2001**, 48, 151-9 | 3.5 | 27 |
| 27 | SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. *Journal of Biological Chemistry*, **2001**, 276, 2451-8 | 5.4 | 47 |
| 26 | Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. *Journal of Biological Chemistry*, **2000**, 275, 6868-75 | 5.4 | 164 |

| | | | |
|---|---|---|---|
| 25 | Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. *Oncogene*, **2000**, 19, 3521-8 | 9.2 | 208 |
| 24 | Case 1: small bowel obstruction due to metastatic lung cancer. *Journal of Clinical Oncology*, **2000**, 18, 227-8 | 2.2 | 14 |
| 23 | The noncatalytic domain of protein-tyrosine phosphatase-PEST targets paxillin for dephosphorylation in vivo. *Journal of Biological Chemistry*, **2000**, 275, 1405-13 | 5.4 | 60 |
| 22 | The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. *Journal of Biological Chemistry*, **2000**, 275, 24273-8 | 5.4 | 248 |
| 21 | Molecular cloning and characterization of human trabeculin-alpha, a giant protein defining a new family of actin-binding proteins. *Journal of Biological Chemistry*, **1999**, 274, 33522-30 | 5.4 | 35 |
| 20 | The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. *Journal of Biological Chemistry*, **1999**, 274, 36684-92 | 5.4 | 111 |
| 19 | Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. *Oncogene*, **1999**, 18, 67-77 | 9.2 | 74 |
| 18 | Involvement of the adapter protein CRKL in integrin-mediated adhesion. *Oncogene*, **1999**, 18, 3343-53 | 9.2 | 28 |
| 17 | Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). *Journal of Biological Chemistry*, **1997**, 272, 10248-53 | 5.4 | 81 |
| 16 | Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. *Journal of Biological Chemistry*, **1997**, 272, 4230-6 | 5.4 | 98 |
| 15 | The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. *Journal of Biological Chemistry*, **1997**, 272, 33373-6 | 5.4 | 75 |
| 14 | Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). *Journal of Biological Chemistry*, **1997**, 272, 14320-6 | 5.4 | 80 |
| 13 | Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. *Cytokine and Growth Factor Reviews*, **1997**, 8, 63-79 | 17.9 | 95 |
| 12 | Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. *Leukemia and Lymphoma*, **1997**, 28, 65-72 | 1.9 | 36 |
| 11 | The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. *Oncogene*, **1997**, 15, 2379-84 | 9.2 | 71 |
| 10 | Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. *Journal of Cellular Physiology*, **1997**, 171, 28-33 | 7 | 34 |
| 9 | Role of focal adhesion proteins in signal transduction and oncogenesis. *Critical Reviews in Oncogenesis*, **1997**, 8, 343-58 | 1.3 | 50 |
| 8 | The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. *Journal of Biological Chemistry*, **1996**, 271, 31222-6 | 5.4 | 116 |

| | | | |
|---|---|---|---|
| 7 | p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. *Journal of Biological Chemistry*, **1996**, 271, 25198-203 | 5.4 | 104 |
| 6 | CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. *Journal of Biological Chemistry*, **1995**, 270, 29145-50 | 5.4 | 97 |
| 5 | Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. *Journal of Biological Chemistry*, **1995**, 270, 5039-47 | 5.4 | 220 |
| 4 | Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. A case report. *Cancer*, **1994**, 74, 1887-90 | 6.4 | 7 |
| 3 | Altered membrane fluidity in rat hepatocytes during endotoxic shock. *Molecular and Cellular Biochemistry*, **1993**, 121, 143-8 | 4.2 | 10 |
| 2 | A Non-genetic Mechanism for Chemoresistance in Lung Cancer: The Role of Integrin β1/Paxillin Axis | | 1 |
| 1 | Suppressing chemoresistance in lung cancer via dynamic phenotypic switching and intermittent therapy | | 3 |